NSEAnalysts/Institutional Investor Meet/Con. Call Updates1d ago · 21 Sept 2026, 02:52 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Glenmark Pharmaceuticals Limited · GLENMARK

✦ AI Summary

Glenmark Pharmaceuticals has informed the Exchange about the schedule of an Analyst/ Institutional Investor meeting to be conducted on 29-09-2026 at PL Capital - Emerging Titans Mumbai Physical Both 2026 Conference.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet

Attachments (1)

📄

GLENMARK_21092026145007_SE_Investor_Meet.pdf

pdf

Download →
View document text
September 21, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 56/26-27 Our Reference No. 56/26-27 Dear Sir/ Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) - Schedule of Analyst/ Institutional Investor Meetings With reference to the captioned subject and pursuant to the Regulation 30 and Para A of Part A of Schedule III of the SEBI LODR, we would like to inform details of the Analyst/ Institutional Investor meeting to be conducted as follows: Analyst/Institutional Type of Group / Date Venue Investors/Event Meeting One-on-one 29-09-2026 PL Capital - Emerging Titans Mumbai Physical Both 2026 Conference The schedule of the above-mentioned meeting may undergo changes due to exigencies on the part of Investor/ Company. Kindly note that no unpublished price sensitive information is proposed to be shared during the meeting. We request you to take this intimation on record. Thanking you. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com